BENGALURU: Biocon is betting big on new product launches in its generics and biosimilars portfolios, which are expected to fuel its expansion in the next 2-3…
Trending
- Axis Securities slammed with Rs 10 lakh penalty for violating stock brokers rules
- Indian stocks to swing in ‘corrective to consolidation’ phase for next 3 to 4 months: Report
- Appropriate time for a rate cut: RBI governor in policy meet
- RBI plans $10 billion dollar-Re swap to improve liquidity
- Satcom policy shouldn’t discriminate against terrestrial cos: Sunil Mittal
- Tata Capital board to look at potential fund-raise
- Unions plan 1-day strike against Samsung
- India needs to cut tariffs for its own good, says Niti CEO
- Supertech realty projects: Supreme court stays NCLAT’s order, invites alternatives from stakeholders
- RBI imposes Rs 46 lakh penalty on three firms for non compliace
